AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04800315 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dosages on specified days
Study NCT05422976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVI-01
Description: High molecular weight Hyaluronic Acid
Study NCT04480086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivebresib
Description: Tablet: Oral
Study NCT04480086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral
Study NCT04480086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral
Study NCT06065150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard support
Description: See arm/group descriptions
Study NCT06065150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early surgery proposed according to the radiological score
Description: * If score ≥ 5: the risk of medical treatment failure is multiplied by 2.9 (Feuerstoss F et al, J Gastrointest Surg 2021). Early surgical treatment is proposed; that is, the procedure is performed within 24 hours of admission. The surgery is initiated by laparoscopy and converted to open surgery if necessary.~* If score \< 5: the risk of medical treatment failure is reduced. Initial medical treatment is therefore offered in accordance with standard management.
Study NCT05665842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Application
Description: The Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be applied. After, the predetermined instrumental music will be shared with the adolescents every evening for 15 days via social media by the researcher and participants will be asked to listen to these music. Participants will listen to the instrumental music sent by the researcher for at least 20 minutes every evening during the music application. This whole process will be reminded to the adolescents with messages every evening and they will be asked to listen the music before the normal bedtime (before 23:00 at night). At the end of the music application (after 15 days), the Introductory Characteristics Form for Adolescents, the PedsQL and AIQ will be reapplied. In the music application, the selecting instrumental music will be used. To determine the music, the researcher will be advice received from the TÜMATA and the a music education expert.
Study NCT06526338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% IP-001 for injection
Description: Participants will receive a single injection of 1.0% IP-001 following local ablation or surgical resection and local ablation
Study NCT06526338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Resection and Local Ablation
Description: Participants will undergo surgical resection of the tumor and local ablation by either radiofrequency ablation (RFA ) or microwave ablation (MWA)
Study NCT06526338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection and Local Ablation
Description: Participants will undergo surgical resection of the tumor and local ablation by either radiofrequency ablation (RFA ) or microwave ablation (MWA)
Study NCT06526338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Ablation Alone
Description: Participants will have local ablation of the tumor by either radiofrequency ablation (RFA) or microwave ablation (MWA) alone
Study NCT06526338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Ablation Alone
Description: Participants will have local ablation of the tumor by either radiofrequency ablation (RFA) or microwave ablation (MWA) alone
Study NCT05293145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Building Futures Program Primary Services
Description: Primary Services Participants receive 14 hours of Survival Skills for Healthy Families curricula delivered over a series of 7 weekly workshops. Participants also receive support services delivered by Family Coaches and Career Coaches as needed.
Study NCT05329103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEEL-224
Description: Lyophilized powder reconstituted with D5W
Study NCT05036707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xenodiagnosis Ticks
Description: Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatched from eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors.
Study NCT06309394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.
Study NCT06239623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSI-1187
Description: Use ERK inhibitor JSI-1187 to treat solid tumor
Study NCT05665842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Training
Description: After explaining the purpose of the study and the way it was applied to the adolescents in the music practice group, the Introductory Characteristics Form for Adolescents, the Pediatric Quality of Life Inventory (PedsQL) and Adolescent Insomnia Questionary (AIQ) will be applied.~Adolescents in this group will be trained on Zoom for 4 weeks, 2 times a week, for 8 sessions (1 session 40 min). Sleep hygiene training prepared based on expert opinions and literature (Halal \& Nunes, 2014; Dinis \& Bragança, 2018; İşsever et al., 2021) will be given by the researcher. A Sleep Hygiene Training Booklet will be prepared for use in education and to give to adolescents after education.The Sleep Hygiene training booklet to be prepared will be prepared by the researcher and submitted for expert opinions. Adolescents who received sleep hygiene training will be reapply 15 days after the training, with the PedsQL and AIQ.
Study NCT05036707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin biopsy
Description: 2-3 mm skin punch biopsies will be performed.
Study NCT05036707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood draw
Description: Peripheral blood draws will be performed.
Study NCT06533345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Coaching
Description: Done by Dr. Hollingsworth or students via consultations with participants. Participant's health behavior aspirations or target outcomes will be clarified, informed by the participant's interactions with other MERCI providers. Behaviors that move the participant towards their aspirations/outcomes will be explored to find target behaviors that the participant is motivated and able to do. Target behaviors and supporting habits will be designed into the participant's existing routine. The Fogg Behavior Model will be used 1) to find the participant's primary motivation for engaging in target behaviors and 2) to make target behaviors easier to do. Implementation intentions - When/then or If/then plans - will be used to form habits and promote behavior engagement. Adopting a growth mindset will also be discussed. Subsequent consultations will focus on troubleshooting, iterative improvements, and incorporation of new aspirations/outcomes, target behaviors, and supporting habits.
Study NCT06533345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Nutrition: The nutrition intervention will be conducted as a 12-week protocol with assessment points at baseline, 1 month, and 3 months. Following consent, eligible participants will work through a self-taught educational module detailing the anti-inflammatory dietary program. Once the module is completed, participants will be scheduled for one-on-one counseling sessions with a Registered Dietitian or a supervised Dietetic Intern or Medical Student on the research team to receive personalized guidance on implementation of the dietary intervention. A dietary recall will be conducted via the automated self-administered dietary assessment tool (ASA24®), which takes about 20 minutes to complete. This survey will be conducted on two non-consecutive days at each timepoint (baseline, 1 month, and 3 months).
Study NCT06533345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autonomic Recalibration
Description: Participant will be outfitted with the Empatica wrist sensor. An initial history to rule out pathology and document a chief complaint relevant to pain is conducted. An initial head to toe assessment of withdrawal or startle reflex behavior in response to palpation is performed to identify trigger points and establish patterns of sympathetic dominance. The pattern of sympathetic dominance is addressed during treatment by Primal Reflex Release Technique Protocol to inhibit somatic afferent feedback loops and rebalance the autonomic nervous system towards a state of parasympathetic dominance. Day 2 is the same until the initial history and r/o. Here, the history is from the previous day, asking about perception of pain, sleep, digestion, or other pertinent issues brought up on the first visit. Treatment proceeds same as Day 1. Any emotional tags to trigger points are identified and acknowledged. Subjects may be scheduled for follow-up visits if their pain persists.
Study NCT06533345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: An initial history to document a chief complaint relevant to pain is conducted and to identify and potential contraindications (infection of overlying skin, patient on anticoagulation drugs, 1st trimester of pregnancy, etc.) A physical exam is performed to identify the trigger points causing pain. The subject is educated about the risks/benefits/indications and alternative treatments. The subject is also educated about dry needling aftercare. The skin over the trigger points is cleaned with 70% isopropyl alcohol. The pertinent trigger points are treated with dry needling (95% of time), direct inhibition (2 - 3% of time) or injection of 1% lidocaine in a fan-like fashion (1 - 2 % of the time). Subject is assessed for any bleeding. An office note, including a procedure note, is documented in the subject's record. Subject is scheduled for additional follow-up meeting.
Study NCT06533345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic Manipulative Treatment: After inform and consent process, the subject will enter patient room and meet with Dr. Hayes, who will conduct a brief history of patient pain, injuries, and procedures. Subjects will be asked to wear, or change into, athletic shorts or a tank top or loose-fitting T-shirt to facilitate treatment. Subject will undergo a brief somatic dysfunction screen, which involves light tough and manipulation. Once Hayes has diagnosed potential dysfunctions, he will proceed with osteopathic manipulative treatment. Treatment will last anywhere from 15 minutes to 1 hour. At the end of the treatment, subjects will be scheduled for a follow-up visit.
Study NCT06533345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Psychology
Description: Psychoeducation Workshop and Counseling: The psychoeducational group intervention will be done according to the standardized Empowered Relief (Darnall et al., 2024) protocol. Empowered Relief is a single-session, 2-hour group workshop (online or in person) that teaches participants pain neuroscience education, mindfulness principles, and cognitive-behavioral skills. During the program, participants will complete a personalized plan to work toward pain relief. This program requires a certified instructor; Marilyn Cornish (Co-I), a licensed psychologist, is certified. After completion, participants can attend up to 4 individual counseling sessions with a counseling psychology doctoral student (supervised by Marilyn Cornish). Sessions will be approximately 50-60 minutes and will occur every other week. Specific in-session interventions will be tailored to the participant's unique needs but will focus on participants' pain relief plan and overall psychological wellbeing of participants.
Study NCT05880043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-102
Description: GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
Study NCT05062395 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo FDG PET CT
Study NCT05062395 — intervention group
Intervention type: OTHER
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET CT
Study NCT05062395 — intervention group
Intervention type: OTHER
Intervention: Low Carbohydrate High Fat Diet
Description: low carbohydrate and high fat diet for 48-72 hours
Study NCT05062395 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo FDG PET CT
Study NCT06397521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crown lengthening
Description: Investigation of the three techniques for aesthetic crown lengthening
Study NCT06533345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Treatments
Description: Subjects receiving multiple treatment interventions over the same period of time.~Example: A subject joins the Osteopathic Manipulative Treatment group and meets with Dr. Hayes for treatment visits. At the same time, they are meeting with Dr. Kirby in a separate visit (or at the same time, if scheduling allows) to discuss Nutrition. Any subjects who were in multiple/overlapping treatment groups will fit this description.
Study NCT05758155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mental health literacy training supported by creative drama
Description: nursing students will be given two hours of mental health literacy training supported by creative drama one day a week for 4 weeks.
Study NCT05758155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mental health literacy training supported by classroom instruction
Description: nursing students will be given mental health literacy training supported by two hours of classroom instruction one day a week for 4 weeks.
Study NCT05627115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab, AVD, Radiotherapy
Description: GROUP A: Early stage disease without adverse features in CMR: 2 further cycles tislelizumab then radiotherapy then 200mg IV tislelizumab once every 3 weeks until a maximum of 2 years total treatment. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP B: Early stage disease with adverse features in CMR: 2 cycles of AVD plus tislelizumab then radiotherapy. PET-CT (PET2) 12 weeks after the completion of radiotherapy.~GROUP C: All early stage disease not in CMR: 4 cycles of AVD plus tislelizumab then PET-CT and radiotherapy. PET-CT 12 (PET2) weeks after radiotherapy.~GROUP D: Advanced stage disease in CMR: 4 cycles of AVD plus tislelizumab then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.~GROUP E: Advanced stage disease not in CMR: 6 cycles of AVD plus tislelizumab then PET-CT then radiotherapy at investigator's discretion. PET-CT (PET2) 12 weeks after radiotherapy.
Study NCT04553094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Aerobic circuit training
Study NCT06479720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined pharmacotherapy with Solifenacin and Mirabegron
Description: Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.
Study NCT06649994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active iTBS of the DLPFC
Description: Participants will receive a 3 minutes intermittent Theta Burst Stimulation of the DLPCF of the left hemisphere while not performing any other task
Study NCT06479720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin with vaginal estrogen cream
Description: Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
Study NCT06479720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron with vaginal estrogen cream
Description: Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).
Study NCT06649994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active iTBS of the vmPFC
Description: Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vmPFC while not performing any other task
Study NCT06649994 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: iTBS of the vertex (sham)
Description: Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vertex while not performing any other task
Study NCT06649994 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized inhibitory control training
Description: Participants will perform the task of the FoodT app for 10 minutes immediately after iTBS (taking advantage of time of maximum brain potentiation, Rossi et al., 2009).~This task pairs high-calorie meals with the no-go cue. Images appear on the left, right or center of the smartphone screen and they must touch it or not (depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses: If the image has a green border around it, you must tap the image and win 1 point. But if the image has a red border around it, you must inhibit the tapping response or you will lose 1 point. Participants must respond as quickly and accurately as possible and improve reaction time.~Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal
Study NCT06649994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized inhibitory control training
Description: Participants will perform the task of the FoodT app for 10 minutes immediately after iTBS (taking advantage of time of maximum brain potentiation, Rossi et al., 2009).~This task pairs high-calorie meals with the no-go cue. Images appear on the left, right or center of the smartphone screen and they must touch it or not (depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses: If the image has a green border around it, you must tap the image and win 1 point. But if the image has a red border around it, you must inhibit the tapping response or you will lose 1 point. Participants must respond as quickly and accurately as possible and improve reaction time.~Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal
Study NCT05729594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost Ophthalmic
Description: eyedrops
Study NCT05729594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Ophthalmic
Description: eyedrops
Study NCT05391165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back school
Description: Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
Study NCT05132166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
Description: Will vary depending upon Investigator's choice identified prior to randomization. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT. No cross-over to DSC treatment is planned. The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
Study NCT05132166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual Stromal Cells
Description: The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
Study NCT04905862 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immune response
Description: 1. Venous blood samples will be collected at seven-time points: before dose 1 of vaccine, 21 days after dose 1, within 14-21 days after dose 2 and 3,6,9,12 months after vaccination. From the volume of about 8 ml of the patient's peripheral blood, a fraction of PBMC (peripheral blood mononuclear cells) will be isolated.~2. The level of antibodies against the SARS-CoV-2 nucleocapsid (N) antigen will be detected in serum using the Abbot Architect™SARS-CoV-2 IgG test.~3. The level of neutralizing IgG and IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S) will be detected in serum using the DiaSorin LIAISON®SARS-CoV-2 S1/S2 IgG serology COVID-19 S-Protein (S1RBD) Human IgA ELISA Kit respectively.~4. The cellular component of the immune response will be tested using the ELISPOT method, which involves testing the amount of INF-γ and IL-2 released from leukocyte cells.
Study NCT04905862 — intervention group
Intervention type: OTHER
Intervention: Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events
Description: The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials. Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination. Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
Study NCT06600906 — intervention group
Intervention type: DRUG
Intervention: Hyperpolarized 13C-Pyruvate
Description: Given intravenously (IV)